You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to August 2024

AbstractFullPdf
Nov 202131908
Dec 20215604
Jan 20226009
Feb 20226804
Mar 2022246019
Apr 2022190014
May 2022140023
Jun 2022100014
Jul 20228007
Aug 202292012
Sep 20227806
Oct 2022104011
Nov 202268010
Dec 20225203
Jan 20235406
Feb 202388013
Mar 2023108012
Apr 202390013
May 202362014
Jun 20235608
Jul 202384015
Aug 202310007
Sep 20236805
Oct 20237608
Nov 2023110016
Dec 20236405
Jan 20243405
Feb 20247207
Mar 202494011
Apr 202488018
May 20246407
Jun 20245606
Jul 202492016
Aug 202490019
Total32030355